Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
Podcasts
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
infliximab
Email alerts
infliximab
True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α?
M H
Buch
,
P G
Conaghan
,
M A
Quinn
,
S J
Bingham
,
D
Veale
,
P
Emery
Annals of the Rheumatic Diseases
Oct 2004,
63
(10)
1344-1346;
DOI:
10.1136/ard.2003.014878
Empyema in a patient treated with infliximab: it is not what it seems
A
Bossink
,
S
Thijsen
,
A J
van Houte
Annals of the Rheumatic Diseases
Nov 2005,
64
(11)
1657-1658;
DOI:
10.1136/ard.2004.034959
Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment
S N
Nikas
,
P V
Voulgari
,
I P
Takalou
,
P
Katsimbri
,
A A
Drosos
Annals of the Rheumatic Diseases
Nov 2005,
64
(11)
1665-1667;
DOI:
10.1136/ard.2005.036178
Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales
P
Geborek
,
E
Nitelius
,
S
Noltorp
,
H
Petri
,
L
Jacobsson
,
L
Larsson
,
T
Saxne
,
I
Leden
Annals of the Rheumatic Diseases
Dec 2005,
64
(12)
1805-1807;
DOI:
10.1136/ard.2005.036715
Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab
A
Kuuliala
,
R
Nissinen
,
H
Kautiainen
,
H
Repo
,
M
Leirisalo-Repo
Annals of the Rheumatic Diseases
Jan 2006,
65
(1)
26-29;
DOI:
10.1136/ard.2004.034728
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy
E
Kruithof
,
D
Baeten
,
F
Van den Bosch
,
H
Mielants
,
E M
Veys
,
F
De Keyser
Annals of the Rheumatic Diseases
Apr 2005,
64
(4)
529-536;
DOI:
10.1136/ard.2003.018549
Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12
M
van Oosterhout
,
E W N
Levarht
,
J K
Sont
,
T W J
Huizinga
,
R E M
Toes
,
J M
van Laar
Annals of the Rheumatic Diseases
Apr 2005,
64
(4)
537-543;
DOI:
10.1136/ard.2004.024927
Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice
N
Neven
,
M
Vis
,
A E
Voskuyl
,
G J
Wolbink
,
M T
Nurmohamed
,
B A C
Dijkmans
,
W F
Lems
Annals of the Rheumatic Diseases
Apr 2005,
64
(4)
645-646;
DOI:
10.1136/ard.2004.028597
Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment
K
Laas
,
R
Peltomaa
,
H
Kautiainen
,
K
Puolakka
,
M
Leirisalo-Repo
Annals of the Rheumatic Diseases
Jul 2006,
65
(7)
924-928;
DOI:
10.1136/ard.2005.041574
Case Number 29: Hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade)
C
Fiehn
,
K
Andrassy
Annals of the Rheumatic Diseases
Mar 2004,
63
(3)
232;
DOI:
10.1136/ard.2003.014191
Pages
« first
‹ previous
1
2
3
next ›
last »
CLINICAL
Diagnostics
Clinical diagnostic tests
(1563)
Radiology (diagnostics)
(921)
Surgical diagnostic tests
(505)
Drugs and medicines
Endocrinology
Calcium and bone
(938)
Evidence based practice
Guidelines
(35)
Gastroenterology
Inflammatory bowel disease
(98)
Genetics
(1272)
Immunology (including allergy)
(6648)
Infectious diseases
Bone and joint infections
(93)
Travel medicine
(42)
Neurology
Muscle disease
(198)
Pain (neurology)
(1113)
Nutrition and metabolism
Obesity (nutrition)
(142)
Obstetrics and gynaecology
Menopause (including HRT)
(60)
Ophthalmology
(155)
Orthopaedics
Pathology
Inflammation
(1572)
Pathology
(531)
Pharmacology and therapeutics
Unwanted effects / adverse reactions
(15)
Pharmacology and therapeutics
Radiology
(1357)
Rehabilitation medicine
Disability
(32)
Other rehabilitative therapies
(18)
Physiotherapy
(52)
Renal medicine
(247)
Respiratory medicine
Interstitial lung disease
(181)
Pulmonary hypertension
(39)
Rheumatology
Ankylosing spondylitis
(567)
Biological agents
(731)
Connective tissue disease
(5506)
Degenerative joint disease
(6038)
Drugs: musculoskeletal and joint diseases
(916)
Fibromyalgia
(51)
Musculoskeletal syndromes
(6412)
Osteoarthritis
(1189)
Osteoporosis
(160)
Rheumatoid arthritis
(4213)
Sjogren's syndrome
(6)
Systemic lupus erythematosus
(724)
Vascularitis
(367)
Sports and exercise medicine
Physiotherapy
(33)
NON-CLINICAL
Epidemiology
(1862)
Health economics
(51)
Medical education
Postgraduate
(5)
Occupational and environmental medicine
(32)
Statistics and research methods
Special collections
ARD Lay summaries
(83)
Editor's choice
(161)
Guidelines, Recommendations and Consensus Statements
Open access
(1199)
Press releases
(50)
